Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Leukemia, Promyelocytic, Acute

• Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
• Optimum Induction Therapy of Low-risk APL
• Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL.
• A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
• Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
• Frontline Oral Arsenic Trioxide for APL
• Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
• Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
• Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
• Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
• Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
• Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
• PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
• PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
• Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
• A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
• Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
• Proteasome Inhibition in Acute Promyelocytic Leukemia
• A Safety Study of SGN-CD33A in AML Patients
• Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
• Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
• Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
• Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
• Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
• Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
• Veliparib and Temozolomide in Treating Patients With Acute Leukemia
• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
• Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
• AIDA 2000 Guidelines
• Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
• Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
• Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
• Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
• Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
• New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• APL93: Timing of CxT and Role of Maintenance
• A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
• S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
• Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
• Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
• Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
• Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
• S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
• Phase III Trial in Acute Promyelocytic Leukemia Patients
• Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
• All-trans Retinoic Acid, and Arsenic +/- Idarubicin
• Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
• Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
• Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
• Vorinostat in Treating Patients With Acute Myeloid Leukemia
• 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
• Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
• Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
• Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
• AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
• Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
• SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
• Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
• Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
• Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
• Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
• Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
• Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
• Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission